Summary
Revenue rose 32.6% to $4.06 million in FY2018 Q4. Operating income was $0.34 million, swinging to a profit from an operating loss in the prior-year quarter. Net income was $0.64 million, also swinging to a profit. Diluted EPS was $0.03, compared with a loss in the prior-year quarter. Operating margin was 8.5%, up 30.4 percentage points. The quarter's profitability improved as revenue rose. The company adopted ASC 606 using the full retrospective method, which restated certain previously reported results.
For the full year, revenue was $16.13 million, up 4.3%. Operating income was $0.38 million, down 65.6%. Net income was $1.23 million, up 23.2%. Diluted EPS was $0.06, up 20.0%. Operating margin was 2.4%, down 4.8 percentage points. Deferred revenue was $3.10 million, up 5.7%. Remaining performance obligations were $0.10 million, and the company expects to recognize revenue on approximately 97% of those obligations over the next 12 months. Operating cash flow was $0.66 million, down 82.0%. Capital expenditures were $0.21 million, up 151.2%. In Q4, operating cash flow was $2.82 million, down 7.7%, and capital expenditures were $0.06 million, up 204.8%.
The revenue mix shifted. Software license revenue decreased 12% and represented 50% of total revenue in 2018, down from 59% in 2017. Biometrics license sales improved because of a large commercial customer and a systems integrator agreement, while imaging license sales fell. Services revenue increased 114% and was 17% of total revenue, up from 8%, driven by the systems integrator project. Software maintenance revenue increased 10% and was 33% of total revenue, up from 32%. Royalties decreased 100% to zero and were 1% of total revenue in 2017. Research and development expense decreased 9% and was 44% of total revenue, down from 50%. Selling and marketing expense increased 7% and was 26% of total revenue, up from 25%. General and administrative expense decreased 3% and was 20% of total revenue, down from 22%. Cost of services increased 103%, while cost of software licenses decreased 93%. Engineering headcount increased by two in 2018.
Management expects development work on the systems integrator project to continue for approximately the next two to three quarters. It also expects further cost of services from that project over the next two to three quarters. Services gross margins are expected to fluctuate based on project nature, complexity, and pricing. The company does not consider DSL royalties a key element of the business and believes it is unlikely to receive DSL royalties in future periods. Patent sales are likely to be minimal because remaining patents and applications pertain primarily to biometrics and imaging compression. The filing states cash and cash equivalents will be sufficient to fund operations for at least the next twelve months. It also states that no valuation allowance is recorded against deferred tax assets, but a valuation allowance would be required if evidence about realizability changes. The Internal Revenue Service completed an examination of the company's 2015 tax return in February 2018 with no changes to reported tax.
Risks center on the large systems integrator project and its timing. The project is expected to last two to three more quarters, and services margins can move with project mix. Government customer revenue was lower, and imaging license revenue declined. The company also faces uncertainty around patent income. Services backlog was $0.7 million at December 31, 2018. Operating cash flow fell sharply for the full year, even though Q4 operating cash flow was $2.82 million. The company has no material commitments for capital expenditures and no off-balance sheet arrangements. Financing activities used cash for stock repurchases and employee tax withholding, while the company continues to rely on existing cash balances and cash from operations. The company believes its engineering organization was adequately staffed as of December 31, 2018.
Forecast
No forward guidance in this quarter's filings.
Reported figures
GAAP, from SEC filings| Metric | Q4 FY2018 | Q3 FY2018 | QoQ | Q4 FY2017 | YoY |
|---|---|---|---|---|---|
| Revenue | $4.1M | $5.4M | -24.9% | $335.0K | +1111.3% |
| Research & development | $1.5M | $1.8M | -16.0% | $1.9M | -19.0% |
| Sales & marketing | $944.0K | $1.3M | -27.2% | $1.0M | -5.7% |
| General & administrative | $833.0K | $807.0K | +3.2% | $935.0K | -10.9% |
| Total operating expenses | $3.8M | $4.3M | -11.2% | $3.9M | -3.6% |
| Operating income (loss) | $343.0K | $1.1M | -70.0% | -$478.0K | +171.8% |
| Operating margin | 8.4% | 21.1% | -12.7 pp | -142.7% | +151.1 pp |
| Net income (loss) | $639.0K | $1.3M | -50.0% | -$581.0K | +210.0% |
| Net margin | 15.8% | 23.6% | -7.9 pp | -173.4% | +189.2 pp |
| Diluted EPS | $0.03 | $0.06 | -$0.03 | -$0.03 | +$0.06 |
Risks
Risk factors state individual orders can represent a meaningful percentage of quarterly revenue and that failure to close, deferral, or cancellation can cause revenue and net income shortfalls. MD&A highlights a Q2 2018 systems integrator software license agreement that contributed $1.8 million of software license revenue in 2018 and a Q3 2018 large commercial customer, while total revenue for FY2018 year to date rose 4.3% to $16.13 million.
A significant portion of revenue is derived directly or indirectly from federal, international, state and local governments. Risk factors cite changes in fiscal policy, funding priorities, appropriations delays, and government payment delays; MD&A notes lower revenue from government customers partially offset 2018 biometrics license growth.
The company derives a significant portion of revenue from third party systems integrators and OEM partners, and risk factors warn that partner sales reductions, failure to win government awards, or termination of a major partner relationship could materially harm results. MD&A says a large Q2 2018 systems integrator project is expected to continue for approximately the next two to three quarters.
Risk factors describe intense competition from diversified providers such as Idemia, Gemalto, and NEC and component providers such as Cognitec, Neurotechnology, Iritech, Nuance, and Innovatrics, with many competitors having greater financial, marketing, and research resources and low cost foreign competitors willing to cut prices.
Growth strategy depends on expanding biometrics into commercial markets, but risk factors say commercial acceptance is limited and biometrics competes with traditional security methods. MD&A notes a Q3 2018 large commercial customer helped biometrics license revenue, but imaging software license sales fell to $0.9 million in 2018 from $3.2 million in 2017.
The biometrics industry is characterized by rapid technological change and evolving standards; failure to develop new capabilities or correctly choose technical alternatives could render existing products obsolete and cause customers to buy competitors' products.
Patent related income fell to $69,000 in 2018 from $1.6 million in 2017, and royalties decreased 100% from $0.1 million in 2017 to zero in 2018. MD&A says future patent sales are likely to be minimal and DSL royalties are unlikely in future periods.
Operating cash flow for FY2018 year to date was $0.66 million, down 82.0% from $3.67 million in FY2017 year to date, primarily due to $1.5 million of changes in assets and liabilities. MD&A states cash and cash equivalents were $51.6 million at December 31, 2018 and believes they are sufficient for at least the next twelve months.
Extensive federal, state, and foreign regulation, including privacy and data protection changes such as the EU General Data Protection Regulation, could affect use of products and services and impose compliance costs. Tariffs, import restrictions, and export restrictions could also harm the business.
The company is subject to income taxes in the United States and significant judgments are required; tax returns are subject to IRS and state examinations, and an ultimate tax determination in excess of accrued amounts could adversely affect operating results, cash flows, and financial condition. MD&A notes $5.2 million of deferred tax assets with no valuation allowance as of December 31, 2018.
SaaS KPIs
All quarters →Services Backlog
Summary, forecast, risks and KPIs are extracted from AWARE INC /MA/'s SEC filings for Q4 FY2018 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Nov 12, 2026.